← HighTide Therapeutics overview

HighTide Therapeutics vs Akeso: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

HighTide Therapeutics Inc (2511.HK)

Akeso Inc (9926.HK)

Q3 2026
▲3▼1

Ivonescimab's Phase 3 Win and FDA Path Drive Akeso Higher

  • Ivonescimab's Phase 3 Win and Third China Approval Ivonescimab beat Keytruda in a Phase 3 trial, cutting death risk 27%, and won a third China lung-cancer approval. This validates the drug's potential and boosts investor confidence.

    This is the major clinical and regulatory success that drove positive sentiment.

  • AstraZeneca's $2B Investment in Summit AstraZeneca's $2B investment in partner Summit Therapeutics signals strong external confidence in ivonescimab and provides resources for global development, lifting Akeso's shares.

    This partnership news directly boosted investor confidence and provided validation.

  • Pipeline Expansion and Sector Momentum New ADC and cadonilimab trials expanded the pipeline, while record Chinese presence at ESMO and sector momentum added to positive sentiment, supporting the stock.

    These developments show progress and broader industry support, contributing to the stock's rise.

  • Clinical and Regulatory Risks Ivonescimab's benefit was weaker and not statistically reliable in lower-PD-L1 patients, most pipeline programs are years from revenue, and US market access is still draft-stage, posing risks.

    These are the key counterweights that could limit upside and create uncertainty.

September 2026
▲3

Akeso's ivonescimab bests Keytruda; pipeline and partner investment lift outlook

  • Ivonescimab beats Keytruda in Phase 3 lung cancer trial Akeso's ivonescimab cut the risk of death by 27% versus Keytruda in a Phase 3 lung-cancer trial, with a 42% reduction in high-PD-L1 patients. This strong data boosts confidence in the drug's competitiveness.

    This is the major new clinical catalyst that directly supports the stock's potential.

  • AstraZeneca's $2B investment in Summit lifts Akeso AstraZeneca invested $2 billion in Summit Therapeutics, Akeso's partner for ivonescimab. This boosts confidence in the drug's global potential and could accelerate US licensing and development.

    This new partnership validates the drug and improves Akeso's royalty prospects.

  • Two new ADCs enter Phase 1; cadonilimab advances Akeso started Phase 1 trials for two new antibody-drug conjugates (ADCs) and advanced cadonilimab into global and new-indication trials. These early-stage programs add to the pipeline but are years from revenue.

    Shows pipeline progress but also highlights that most revenue is still far off.

  • Weaker lower-PD-L1 benefit and early-stage pipeline temper optimism Ivonescimab's benefit was weaker and not statistically reliable in lower-PD-L1 patients, and most pipeline programs are early-stage. US policy access remains draft-stage, leaving regulatory risk.

    Provides a balanced view of the risks that could limit upside.

Latest
▲4

Akeso's pipeline expands as U.S. opens door to Chinese drug deals

  • U.S. rules may let Chinese drug licensing deals go ahead Washington is drafting rules that would likely allow U.S. drugmakers to license medicines from Chinese biotechs, excluding weaponizable biotech. Akeso shares jumped 8% on the news. If it holds, Akeso keeps access to the big, high-priced U.S. market — the main reason its pipeline is worth so much.

    This is the single biggest new force on Akeso's price: it protects the overseas licensing route that underpins its valuation.

  • AstraZeneca puts $2B into Summit and will test ivonescimab combos AstraZeneca will invest $2 billion in Summit, Akeso's overseas partner, and lead trials combining Akeso's ivonescimab with its own cancer drugs in gut tumors. A global pharma giant funding and running studies raises confidence in ivonescimab's overseas path and cuts Akeso's own development risk.

    A major partner's money and trial backing directly strengthens the case for Akeso's flagship drug abroad.

  • Cadonilimab moves into global and new-indication trials Akeso started a global Phase III gastric-cancer trial for cadonilimab and dosed the first patient in a Phase III colon-cancer study, where earlier data showed an 84.6% complete response. Each new indication widens the drug's future sales base, though revenue is still years away.

    These trials expand the long-term sales potential of Akeso's second big drug beyond its current approved uses.

  • Ivonescimab data and new combo trial keep pipeline momentum Positive survival data for ivonescimab in biliary tract cancer was picked for ESMO's top session, with about 30 bispecific studies to be presented. A Phase II breast-cancer trial combining a new ADC with ivonescimab also began. More proof points support the drug's breadth, but they are early-stage.

    It shows the flagship drug and pipeline are still producing data that can support future approvals and sales.

▲4

Akeso's lung-cancer drug beats Keytruda on survival; two new ADCs enter clinic

  • Ivonescimab beats Keytruda on overall survival Akeso's ivonescimab cut the risk of death by 27% versus Merck's Keytruda in a China Phase 3 lung-cancer trial, with patients living a median 30.8 months versus 22.6. This is the strongest proof yet that Akeso's flagship drug may be better than the world's best-selling cancer drug, lifting its long-term sales outlook.

    The survival win is the period's biggest value driver for 9926.HK.

  • Benefit strongest in high PD-L1 patients In patients whose tumors had high PD-L1 levels, ivonescimab cut death risk by 42%. In lower-PD-L1 patients the benefit was smaller and not statistically reliable. So the drug's edge is real but narrower than headlines suggest, which tempers how much extra sales investors should assume.

    It is the honest counterweight inside the same trial result.

  • Global confirmatory trial and FDA decision ahead Summit is recruiting 780 patients for HARMONi-7, a global trial testing ivonescimab against Keytruda, and the FDA is reviewing a separate application in previously treated EGFR-mutated lung cancer with a November 14 decision date. Success would open the much larger U.S. and European markets.

    It shows the path from China approval to global revenue.

  • Two new ADCs cleared for human testing China's drug regulator cleared Phase 1 trials for AK157D1, a B7-H3 ADC, and AK158D1, a bispecific EGFR/TROP2 ADC. These are Akeso's third and fourth ADCs to reach the clinic, showing a deep pipeline beyond ivonescimab, though any revenue is years away.

    Pipeline breadth supports the long-term growth story.

August 2026
▲4

Akeso's ivonescimab wins third China lung-cancer approval; pipeline advances

  • New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

    This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

  • Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

    It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

  • Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

    It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

  • Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

    It explains the market backdrop pushing the whole sector, including Akeso, higher this period.

▲4

Akeso's ivonescimab wins third China lung-cancer approval; pipeline advances

  • New China approval for ivonescimab in squamous lung cancer China's drug regulator approved ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer — the drug's third approved lung-cancer use. More approved uses mean more patients can be treated, supporting future sales and royalties for Akeso.

    This is the period's biggest company-specific event and directly expands the commercial market for Akeso's lead drug.

  • Ivonescimab's US review and survival data stay on track Partner Summit Therapeutics said the FDA decision on ivonescimab for EGFR-mutant lung cancer is expected by November 14, 2026, and updated survival data showed a consistent benefit across Western and Asian patients. A US approval would open a far larger market and lift Akeso's royalty stream.

    It shows the main global catalyst for Akeso's lead drug is still progressing, which underpins the stock's long-term value.

  • Pipeline push: bispecific ADC combined with ivonescimab Akeso began a Phase II trial of its bispecific ADC AK146D1 combined with ivonescimab in advanced lung cancer, and started a similar breast-cancer study. Early-stage trials are years from sales, but they show the pipeline can produce future growth beyond today's approved drugs.

    It answers what is driving the longer-term story: new pipeline assets that could become future revenue.

  • Sector-wide rally and record China presence at ESMO Chinese drugmakers' oral presentations at ESMO 2026 hit a record 47, with Akeso named a leader, and a broad pharma rally followed strong earnings from WuXi AppTec, BeiGene and Innovent. A rising sector tide can lift Akeso shares even without company-specific news.

    It explains the market backdrop pushing the whole sector, including Akeso, higher this period.